Acrivon Therapeutics (ACRV) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 0.5% versus a loss of 24.5%. Acrivon Therapeutics is the larger company by market cap ($80.1 million vs $78.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | PTHS |
|---|---|---|
| Share price | $1.87 | $20.50 |
| Market cap | $80.14M | $78.48M |
| 1-day change | -0.53% | -2.33% |
| YTD return | -22.41% | -33.87% |
| 1-year return | -0.53% | -24.47% |
| EPS (TTM) | $-1.88 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $37.50 |
| 52-week low | $1.27 | $18.19 |
| Distance from 52-week high | -47.47% | -45.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +514.97% | +159.22% |
| Average volume | 361.40K | 60.07K |
| Shares outstanding | 42.85M | 3.83M |
| Employees | 74 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed PTHS by 23.9 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
ACRV vs PTHS FAQ
Which is bigger, Acrivon Therapeutics or Pelthos Therapeutics?
Acrivon Therapeutics (ACRV) is larger, with a market capitalization of $80.14M compared with $78.48M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, ACRV or PTHS?
ACRV returned -0.53% over the past 12 months, compared with -24.47% for PTHS (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Pelthos Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Acrivon Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Pelthos Therapeutics.